Wuxi PharmaTech Pushing Ahead with $3bn Go-Private Deal
This article was originally published in PharmAsia News
Executive Summary
The continuous development of Wuxi PharmaTech needs ongoing financial support, and while US listing has been an important source for funding, the major Chinese provider of contract development services to the global pharma industry is now looking to go private in a move that aims to take advantage of favorable investor sentiment and bring value to shareholders.
You may also be interested in...
Hisun-Pfizer Split: What Went Wrong And What Next?
The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.